Raytelligence raising SEK 26.3 million for international expansion

21 September 2020

Raytelligence offers products and services for non-contact monitoring vital signs of humans, that is respiration, heartbeat and motion patterns based on the company’s own 60 GHz radar technology.

The Board of Directors has decided, given the consequent acceptance by an Extra Ordinary General Meeting, on an issue of units with preferential rights for existing shareholders amounting to SEK 26.3 million. The capital injection from the rights issue will be used to position Raytelligence as a leading provider of non-contact measurement of vital parameters internationally. The rights issue is secured to 100 per cent through subscription commitments and underwriting.

Augment is acting as financial advisor to Raytelligence in connection with the transaction.

Read full press release here (in Swedish)